We are proud to share a landmark scientific milestone demonstrating the cross-domain capabilities of our Ion Mobility Spectrometry (IMS) technology. Presented at the Schachter International Symposium on Human Chlamydial Infections (ISHCI 2026), a new proof-of-principle study highlights our platform’s success in detecting Chlamydia trachomatis (CT) via infection-based volatilome diagnostics.
Developed in close collaboration with Maastricht University and Microbe&Lab BV, the study utilized Kidod Virion software version 5.0 to analyze patient urine samples by mapping microscopic volatile organic compounds (VOCs).
Our newly optimized analytical algorithm (Algorithm 4) demonstrated exceptional clinical precision against standard laboratory PCR testing:
100% Specificity: Achieved a perfect 100% concordance for all PCR-negative specimens, completely eliminating false positives.
93% High-Load Sensitivity: Delivered a 93% concordance rate among strong PCR-positive specimens ($Ct < 27.5$).
83% General Positive Concordance: Selected as our leading core algorithm for an expanded, large-cohort analysis currently underway.
Traditional PCR-based methods detect nucleic acids, which often persist in a patient’s system for weeks after an infection has naturally cleared or been treated. In contrast, Kidod’s IMS technology tracks active volatile signatures reflecting ongoing metabolic activity and live host-pathogen interactions. This means our platform can differentiate between active, viable infections and residual, inactive DNA.
We extend our deepest thanks to our co-authors and research partners at Maastricht University and Microbe&Lab for advancing the future of rapid, decentralized healthcare.
